- Takeda will pay Innovent a $1.2 billion upfront fee, including a $100 million equity investment.
- IBI363 and IBI343 are late-stage investigational medicines for various cancers.
- IBI3001 is an early-stage bispecific ADC targeting EGFR and B7H3.
- A global Phase 3 study for IBI363 in sqNSCLC is expected to start soon.
Partnership Overview
Takeda has entered a collaboration with Innovent Biologics to develop, manufacture, and commercialize two late-stage oncology drugs, IBI363 and IBI343, outside Greater China. Takeda also has an option to license global rights for the early-stage drug IBI3001.
Financial Details
Innovent will receive a $1.2 billion upfront payment from Takeda, which includes a $100 million equity investment. Additional milestone and royalty payments are possible, along with a 60/40 profit or loss split for IBI363 in the U.S.
Drug Development
IBI363 is a bispecific antibody fusion protein being tested in non-small cell lung and colorectal cancers, with a global Phase 3 study in sqNSCLC expected soon. IBI343 targets the Claudin 18.2 protein in gastric and pancreatic cancers and is in a Phase 3 trial in Japan and China.
Future Plans
Takeda will lead the global co-development and U.S. co-commercialization of IBI363, with exclusive rights outside the U.S. and Greater China. Takeda plans to establish manufacturing for these drugs in the U.S. and expand IBI343 into first-line gastric and pancreatic cancer settings.
